Peer Review History

Original SubmissionFebruary 28, 2022
Decision Letter - Gaurav Varshney, Editor

PONE-D-22-06035Comparative analysis of dCas9-VP64 variants and multiplexed guide RNAs mediating CRISPR activationPLOS ONE

Dear Dr. Miner,

Thank you for submitting your manuscript to PLOS ONE. The manuscript is reviewed by two independent reviewers, and both found it to be useful to the community and have minor concerns. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 29 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Gaurav Varshney, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

5. Review Comments to the Author

Reviewer #1: In this study, authors analyzed multiple combinations of CRISPR/Cas9-mediated activation system. They found dCas9-VP64 and dCas9-p300 combined with MCP-VP64 is more efficient than direct fusion of VP64 to the N-terminus of dCas9 in transcriptional activation for both endogenous and exogenous genes. This study is well-defined and can provide researchers with another efficient tool for gene functional study. However, there are some points that should be revised and addressed by authors so that readers can better understand.

The major point is that the statistical comparisons are unclear and require better clarification.

- Figure 1: The statistical significance was labeled only on some bars. Does this mean only marked bars are significant compared to control? And please clarify the comparisons by drawing lines on the graphs for those were described in text or apply a different symbol as author showed in later figures. Why use two-way ANOVA in this figure?

- Figure 2: 2VP is not significant?

- Figure 3: Not significant for p300 and VP-p300 in ASCL1? p300+MV is not novel? Please double check the statistical significance of VP-p300+MV in ASCL1 and MYOD1.

- Figure4: Only single p300+MV of IL1RN is statistically significant when compared to control? In IL1RN, is multiplexing gRNAs compared to single gRNA of p300+MV that significant (***)?

- Figure 5: Check labeling for statistical comparisons. I see no description for the activity of VP+MV and p300+MV in IL1RN.

Minor points:

- Please unify the labeling by using either control or non-induced control (used in Figure 2) in figure legends.

- Author used abbreviation for all figures except Figure 6, please unify.

- Please consider combining similar figures, for example, Fig. 2 & 3, Fig. 4 & 5 and Fig. 6 & 7.

- Please consider using fluorescent intensity to convey the strength of reporter activation in Figure 6C.

Reviewer #2: The manuscript is a logical and useful extension of previous work on modified CRISPR tools. The methods used are standard and the outcomes are helpful to the research community. While not surprising, the experiment that shows the impact of multiplexing gRNAs targeting a single gene is definitely a useful to researchers.

********** 

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Editor’s comments:

Thank you for submitting your manuscript to PLOS ONE. The manuscript is reviewed by two independent reviewers, and both found it to be useful to the community and have minor concerns. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Reviewers' comments: 

Reviewer #1: In this study, authors analyzed multiple combinations of CRISPR/Cas9-mediated activation system. They found dCas9-VP64 and dCas9-p300 combined with MCP-VP64 is more efficient than direct fusion of VP64 to the N-terminus of dCas9 in transcriptional activation for both endogenous and exogenous genes. This study is well-defined and can provide researchers with another efficient tool for gene functional study. However, there are some points that should be revised and addressed by authors so that readers can better understand.

The major point is that the statistical comparisons are unclear and require better clarification.

- Figure 1: The statistical significance was labeled only on some bars. Does this mean only marked bars are significant compared to control? And please clarify the comparisons by drawing lines on the graphs for those were described in text or apply a different symbol as author showed in later figures. Why use two-way ANOVA in this figure?

RESPONSE: Thank you for taking a careful look at the data. Your thoughts are well taken. Even the groups that do not show a statistical significance are clearly different compared to the non-induced control. The differences are statistically significant with Student’s t test. However, all figures have multiple groups and we used one-way ANOVA multiple comparison analysis. Because there are groups that are clearly different but not significantly different by one-way ANOVA, we have added details of the TTEST and one-way ANOVA analyses to the supporting information (S2 and S3 Tables). Also, we have added a different symbol as we show in the later figures. We apologize for the error in our description. It is actually a one-way ANOVA, not a two-way ANOVA.

- Figure 2: 2VP is not significant?

RESPONSE: 2VP is not statistically significant with one-way ANOVA. (But 2VP is statistically significant with Student’s t-test.).

- Figure 3: Not significant for p300 and VP-p300 in ASCL1? p300+MV is not novel? Please double check the statistical significance of VP-p300+MV in ASCL1 and MYOD1.

RESPONSE: p300 and VP-p300 are not statistically significant with one-way ANOVA. (But they are statistically significant with Student’s t-test.)

- Figure4: Only single p300+MV of IL1RN is statistically significant when compared to control? In IL1RN, is multiplexing gRNAs compared to single gRNA of p300+MV that significant (***)?

RESPONSE: Only p300+MV is statistically significant with one-way ANOVA in the single gRNA expression. (All are statistically significant with Student’s t-test.). Comparison between multiplexing gRNAs to single gRNA of p300+MV is significant with one-way ANOVA (P <0.005).

- Figure 5: Check labeling for statistical comparisons. I see no description for the activity of VP+MV and p300+MV in IL1RN.

RESPONSE: We have added description for the activity of VP+MV and p300+MV on IL1RN in the main text and figure legend. Since we combined Fig 4&5, they correspond to the current Fig 4D.

Minor points:

- Please unify the labeling by using either control or non-induced control (used in Figure 2) in figure legends.

RESPONSE: We apologize for the inconsistency of labels. We have unified the labeling by using non-induced control.

- Author used abbreviation for all figures except Figure 6, please unify.

- Please consider combining similar figures, for example, Fig. 2 & 3, Fig. 4 & 5 and Fig. 6 & 7.

RESPONSE: Thank you for suggestion. We have unified the abbreviation in all figures. Also, we have combined Fig. 4 & 5 and Fig. 6 & 7.

- Please consider using fluorescent intensity to convey the strength of reporter activation in Figure 6C.

RESPONSE: Thanks for the idea to make the data more understandable to the reader. We have added the fluorescent intensity in the lower right corner of each image.

Reviewer #2: The manuscript is a logical and useful extension of previous work on modified CRISPR tools. The methods used are standard and the outcomes are helpful to the research community. While not surprising, the experiment that shows the impact of multiplexing gRNAs targeting a single gene is definitely a useful to researchers.

RESPONSE: Thank you for your supportive comments.

Attachments
Attachment
Submitted filename: PLOS ONE_Rebuttal letter_KO1_JM .docx
Decision Letter - Gaurav Varshney, Editor

Comparative analysis of dCas9-VP64 variants and multiplexed guide RNAs mediating CRISPR activation

PONE-D-22-06035R1

Dear Dr. Miner,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Gaurav Varshney, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Formally Accepted
Acceptance Letter - Gaurav Varshney, Editor

PONE-D-22-06035R1

Comparative analysis of dCas9-VP64 variants and multiplexed guide RNAs mediating CRISPR activation

Dear Dr. Miner:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Gaurav Varshney

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .